A recent study suggests that individuals who come off popular weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt traditional lifestyle plans.
Findings released in a leading health publication points out that while obese individuals can lose substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such drugs must be cognizant of the potential of rapid weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass in about 18 months.
Comparing Treatments
The study, which examined dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that individuals who lose weight through diet and exercise usually see a slower weight regain—around 100 grams monthly—after stopping.
Understanding the Rapid Regain
Doctors propose the mechanism of the jabs is key to understanding the amplified weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal may cause the system to produce less of its endogenous hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of weight regain, the therapy should be considered long-term.
This view is supported by pharmaceutical companies, who say that the findings "highlight the chronic character of obesity," akin to managing diseases like high blood pressure.
Patient Experiences
People who have stopped the jabs report a powerful return of appetite.
"It felt as if a trigger activating and I was suddenly extremely hungry," said one woman.
The struggle is exacerbated if individuals have not adopted permanent lifestyle or habit modifications during treatment.
Significant Use
Figures suggest that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is more common among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, experts stress that while these medications are effective agents for weight loss, they are not a standalone solution and long-term success relies on combined behavioural support.
